Comparative decorporation efficacy of 3,4,3-LIHOPO, 4,4,4-LIHOPO and DTPA after contamination of rats with soluble forms of 238Pu and 233U

Radiat Prot Dosimetry. 2003;105(1-4):535-8. doi: 10.1093/oxfordjournals.rpd.a006298.

Abstract

The aim of this study was to compare the efficacies of DTPA, 3,4,3-LIHOPO and a newly synthesised molecule, 4,4,4-LIHOPO, in removing 233U and 238Pu after internal contamination by soluble forms of those nuclides. For this purpose, intravenous injections of DTPA (30 micromol kg(-1)) or 3,4,3-LIHOPO or 4,4,4-LIHOPO at dosages of 0.3 or 30 micromol kg(-1) were performed 1, 6 and 24 h after contamination of rats by intravenously injected 238Pu citrate and 1 h after intravenous injection of 233U nitrate. Actinide content in the main retention organs and cumulated excretion were measured 48 h after contamination. These experiments show similar decorporation efficacies of 4,4,4-LIHOPO and 3,4,3-LIHOPO for Pu, which are much higher than that of DTPA. At a dosage of 0.3 micromol kg(-1), the two LIHOPO analogues were as efficient as DTPA at a dosage of 30 micromol kg(-1). After U contamination, a 20% decorporation efficacy was obtained for either 3,4,3-LIHOPO or 4,4,4-LIHOPO at a dosage of 30 micromol kg(-1).

Publication types

  • Comparative Study
  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aza Compounds / administration & dosage*
  • Body Burden
  • Chelating Agents / administration & dosage
  • Chelation Therapy / methods*
  • Decontamination / methods*
  • Dose-Response Relationship, Drug
  • Femur / drug effects
  • Femur / metabolism
  • Injections, Intravenous
  • Liver / drug effects
  • Liver / metabolism
  • Male
  • Pentetic Acid / administration & dosage*
  • Plutonium / administration & dosage
  • Plutonium / pharmacokinetics*
  • Plutonium / toxicity
  • Pyridones / administration & dosage*
  • Radiation Injuries / etiology
  • Radiation Injuries / prevention & control*
  • Rats
  • Rats, Sprague-Dawley
  • Treatment Outcome
  • Uranium / administration & dosage
  • Uranium / pharmacokinetics*
  • Uranium / toxicity
  • Whole-Body Counting

Substances

  • Aza Compounds
  • Chelating Agents
  • Pyridones
  • N,N',N'',N'''-tetra(1,2-dihydro-1-hydroxy-2-oxopyridine-6-carbonyl)-1,5,10,14-tetraazatetradecane
  • Uranium
  • Plutonium
  • Pentetic Acid